These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

361 related items for PubMed ID: 23391115

  • 1. Systemic therapy for advanced pancreatic neuroendocrine tumors.
    Kulke MH.
    Semin Oncol; 2013 Feb; 40(1):75-83. PubMed ID: 23391115
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. [Drug therapy for neuroendocrine tumours].
    Tóth M.
    Orv Hetil; 2013 Sep 29; 154(39):1556-64. PubMed ID: 24058101
    [Abstract] [Full Text] [Related]

  • 11. Efficacy and safety of everolimus and sunitinib in patients with gastroenteropancreatic neuroendocrine tumor.
    Yoo C, Cho H, Song MJ, Hong SM, Kim KP, Chang HM, Chae H, Kim TW, Hong YS, Ryu MH, Kang YK, Kim SC, Ryoo BY.
    Cancer Chemother Pharmacol; 2017 Jan 29; 79(1):139-146. PubMed ID: 27942928
    [Abstract] [Full Text] [Related]

  • 12. Implications of the new histological classification (WHO 2010) for pancreatic neuroendocrine neoplasms.
    Crippa S, Partelli S, Boninsegna L, Falconi M.
    Ann Oncol; 2012 Jul 29; 23(7):1928. PubMed ID: 22753260
    [No Abstract] [Full Text] [Related]

  • 13. Pancreatic NETs: where do we stand now?
    Faivre S, Castellano D, Strosberg J, González E, Salazar R.
    Cancer Metastasis Rev; 2014 Mar 29; 33(1):361-6. PubMed ID: 24452757
    [Abstract] [Full Text] [Related]

  • 14. Mutation-targeted therapy with sunitinib or everolimus in patients with advanced low-grade or intermediate-grade neuroendocrine tumours of the gastrointestinal tract and pancreas with or without cytoreductive surgery: protocol for a phase II clinical trial.
    Neychev V, Steinberg SM, Cottle-Delisle C, Merkel R, Nilubol N, Yao J, Meltzer P, Pacak K, Marx S, Kebebew E.
    BMJ Open; 2015 May 19; 5(5):e008248. PubMed ID: 25991462
    [Abstract] [Full Text] [Related]

  • 15. Digestive neuroendocrine tumors (DNET): the era of targeted therapies.
    Boussaha T, Rougier P, Taieb J, Lepere C.
    Clin Res Hepatol Gastroenterol; 2013 Apr 19; 37(2):134-41. PubMed ID: 23562338
    [Abstract] [Full Text] [Related]

  • 16. New target therapies for patients with neuroendocrine tumors of the pancreas.
    Baltogiannis G, Katsios C, Roukos DH.
    Expert Rev Gastroenterol Hepatol; 2011 Oct 19; 5(5):563-6. PubMed ID: 21910571
    [No Abstract] [Full Text] [Related]

  • 17. Targeted agents in treatment of neuroendocrine tumors of pancreas.
    Karampelas IN, Syrigos KN, Saif MW.
    JOP; 2014 Jul 28; 15(4):351-3. PubMed ID: 25076341
    [Abstract] [Full Text] [Related]

  • 18. New treatments of pancreatic neuroendocrine tumors: why using them? How to use them?
    Raymond E, Ruszniewski P.
    Target Oncol; 2012 Jun 28; 7(2):91-2. PubMed ID: 22669625
    [No Abstract] [Full Text] [Related]

  • 19. Circulating biomarkers of response to sunitinib in gastroenteropancreatic neuroendocrine tumors: current data and clinical outlook.
    Mateo J, Heymach JV, Zurita AJ.
    Mol Diagn Ther; 2012 Jun 01; 16(3):151-61. PubMed ID: 22515658
    [Abstract] [Full Text] [Related]

  • 20. Role of biological targeted therapies in gastroenteropancreatic neuroendocrine tumours.
    Yim KL.
    Endocrine; 2011 Oct 01; 40(2):181-6. PubMed ID: 21870172
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.